Metabolomics reveals perturbations in endometrium and serum of minimal and mild endometriosis

• Published in: Scientific reports Vol. 8; no. 1; p. 6466
• Main Authors: Dutta, Mainak, Singh, Brajesh, Joshi, Mamata, Das, Debanjan, Subramani, Elavarasan, Maan, Meenu, Jana, Saikat Kumar, Sharma, Uma, Das, Soumen, Dasgupta, Swagata, Ray, Chaitali Datta, Chakravarty, Baidyanath, Chaudhury, Koel
• Format: Journal Article
• Language: English
• Published: London Nature Publishing Group UK 24-04-2018; Nature Publishing Group
• Subjects: 140/131; 692/308/53/2421; 692/53/2421; Adult; Alanine; Biomarkers - metabolism; Data processing; Diagnosis; Endometriosis; Endometriosis - blood; Endometriosis - classification; Endometriosis - metabolism; Endometrium; Endometrium - metabolism; Female; Glands; Gynecological diseases; Humanities and Social Sciences; Humans; Leucine; Lysine; Metabolism; Metabolites; Metabolome; Metabolomics; Metabolomics - methods; multidisciplinary; NMR; Nuclear magnetic resonance; Phenylalanine; Proline; Science; Science (multidisciplinary); Sensitivity and Specificity; Serum - metabolism; Stroma; Uterus
• ISSN: 2045-2322; 2045-2322
• DOI: 10.1038/s41598-018-23954-7

Endometriosis is a common benign gynecological disease, characterized by growth and proliferation of endometrial glands and stroma outside the uterus. With studies showing metabolic changes in various biofluids of endometriosis women, we have set upon to investigate whether endometrial tissue show differences in their metabolic profiles.
1
H NMR analysis was performed on eutopic endometrial tissue of women with endometriosis and controls. Analysis was performed on spectral data and on relative concentrations of metabolites obtained from spectra using multivariate and univariate data analysis. Analysis shows that various energy, ketogenic and glucogenic metabolites have significant altered concentrations in various stages of endometriosis. In addition, altered tissue metabolites in minimal and mild stages of endometriosis were explored in serum of these patients to assess their role in disease diagnosis. For Stage I diagnosis alanine was found to have 90% sensitivity (true positives) and 58% specificity (true negatives). For Stage II diagnosis alanine, leucine, lysine, proline and phenylalanine showed significant altered levels in serum. While sensitivity of these serum metabolites varied between 69.2–100% the specificity values ranged between 58.3–91.7%. Further, a regression model generated with this panel of serum markers showed an improved sensitivity and specificity of 100% and 83%, respectively for Stage II diagnosis.